BACKGROUND/AIMS: Patterns of metastasis and clinical behavior of mucinous ovarian cancers are poorly understood because of their rarity. METHODS: A retrospective review of records of women identified with pure mucinous invasive ovarian/tubal/peritoneal cancer during 1992-2012 at one institution. Survival differences were compared using Kaplan-Meier methods with log-rank tests. RESULTS: Among 42 women with mucinous adenocarcinomas, the median age was 55 (range 33-83 years). Most cancers were well differentiated (n = 26, 68%) and in stage I/II (n = 31, 74%). One of 27 women with sampled nodes had nodal metastasis; one additional woman had recurrence in a pelvic node. Most had no visible residual tumor after initial surgery, but of 10 women with stage III/IV cancer and documented residual, 8 had >2 cm residual. Except for 1 woman alive with disease at last follow-up, all who had a recurrence died of the disease. Five-year survival was 83% for stage I/II cases but 29% among stage III/IV cases. Stage was a strong predictor of survival (hazard ratio of death among women with stage III/IV cancer 7.73, 95% CI 2.33-25.66, p < 0.001 vs. women with stage I/II cancer). CONCLUSION: Mucinous ovarian cancers have a distinct biology, such that lymphadenectomy for staging is unnecessary and metastatic cancers have poor prognosis.
BACKGROUND/AIMS: Patterns of metastasis and clinical behavior of mucinous ovarian cancers are poorly understood because of their rarity. METHODS: A retrospective review of records of women identified with pure mucinous invasive ovarian/tubal/peritoneal cancer during 1992-2012 at one institution. Survival differences were compared using Kaplan-Meier methods with log-rank tests. RESULTS: Among 42 women with mucinous adenocarcinomas, the median age was 55 (range 33-83 years). Most cancers were well differentiated (n = 26, 68%) and in stage I/II (n = 31, 74%). One of 27 women with sampled nodes had nodal metastasis; one additional woman had recurrence in a pelvic node. Most had no visible residual tumor after initial surgery, but of 10 women with stage III/IV cancer and documented residual, 8 had >2 cm residual. Except for 1 woman alive with disease at last follow-up, all who had a recurrence died of the disease. Five-year survival was 83% for stage I/II cases but 29% among stage III/IV cases. Stage was a strong predictor of survival (hazard ratio of death among women with stage III/IV cancer 7.73, 95% CI 2.33-25.66, p < 0.001 vs. women with stage I/II cancer). CONCLUSION:Mucinous ovarian cancers have a distinct biology, such that lymphadenectomy for staging is unnecessary and metastatic cancers have poor prognosis.
Authors: Richard J Zaino; Mark F Brady; Subodh M Lele; Helen Michael; Benjamin Greer; Michael A Bookman Journal: Cancer Date: 2010-09-22 Impact factor: 6.860
Authors: Helen J Mackay; Mark F Brady; Amit M Oza; Alexander Reuss; Eric Pujade-Lauraine; Ann M Swart; Nadeem Siddiqui; Nicoletta Colombo; Michael A Bookman; Jacobus Pfisterer; Andreas du Bois Journal: Int J Gynecol Cancer Date: 2010-08 Impact factor: 3.437
Authors: Maria B Schiavone; Thomas J Herzog; Sharyn N Lewin; Israel Deutsch; Xuming Sun; William M Burke; Jason D Wright Journal: Am J Obstet Gynecol Date: 2011-06-21 Impact factor: 8.661
Authors: Kathleen M Schmeler; Xia Tao; Michael Frumovitz; Michael T Deavers; Charlotte C Sun; Anil K Sood; Jubilee Brown; David M Gershenson; Pedro T Ramirez Journal: Obstet Gynecol Date: 2010-08 Impact factor: 7.661
Authors: Madalene A Earp; Linda E Kelemen; Anthony M Magliocco; Kenneth D Swenerton; Georgia Chenevix-Trench; Yi Lu; Alexander Hein; Arif B Ekici; Matthias W Beckmann; Peter A Fasching; Diether Lambrechts; Evelyn Despierre; Ignace Vergote; Sandrina Lambrechts; Jennifer A Doherty; Mary Anne Rossing; Jenny Chang-Claude; Anja Rudolph; Grace Friel; Kirsten B Moysich; Kunle Odunsi; Lara Sucheston-Campbell; Galina Lurie; Marc T Goodman; Michael E Carney; Pamela J Thompson; Ingo B Runnebaum; Matthias Dürst; Peter Hillemanns; Thilo Dörk; Natalia Antonenkova; Natalia Bogdanova; Arto Leminen; Heli Nevanlinna; Liisa M Pelttari; Ralf Butzow; Clareann H Bunker; Francesmary Modugno; Robert P Edwards; Roberta B Ness; Andreas du Bois; Florian Heitz; Ira Schwaab; Philipp Harter; Beth Y Karlan; Christine Walsh; Jenny Lester; Allan Jensen; Susanne K Kjær; Claus K Høgdall; Estrid Høgdall; Lene Lundvall; Thomas A Sellers; Brooke L Fridley; Ellen L Goode; Julie M Cunningham; Robert A Vierkant; Graham G Giles; Laura Baglietto; Gianluca Severi; Melissa C Southey; Dong Liang; Xifeng Wu; Karen Lu; Michelle A T Hildebrandt; Douglas A Levine; Maria Bisogna; Joellen M Schildkraut; Edwin S Iversen; Rachel Palmieri Weber; Andrew Berchuck; Daniel W Cramer; Kathryn L Terry; Elizabeth M Poole; Shelley S Tworoger; Elisa V Bandera; Urmila Chandran; Irene Orlow; Sara H Olson; Elisabeth Wik; Helga B Salvesen; Line Bjorge; Mari K Halle; Anne M van Altena; Katja K H Aben; Lambertus A Kiemeney; Leon F A G Massuger; Tanja Pejovic; Yukie T Bean; Cezary Cybulski; Jacek Gronwald; Jan Lubinski; Nicolas Wentzensen; Louise A Brinton; Jolanta Lissowska; Montserrat Garcia-Closas; Ed Dicks; Joe Dennis; Douglas F Easton; Honglin Song; Jonathan P Tyrer; Paul D P Pharoah; Diana Eccles; Ian G Campbell; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Joseph H Rothstein; James M Flanagan; James Paul; Robert Brown; Catherine M Phelan; Harvey A Risch; John R McLaughlin; Steven A Narod; Argyrios Ziogas; Hoda Anton-Culver; Aleksandra Gentry-Maharaj; Usha Menon; Simon A Gayther; Susan J Ramus; Anna H Wu; Celeste L Pearce; Malcolm C Pike; Agnieszka Dansonka-Mieszkowska; Iwona K Rzepecka; Lukasz M Szafron; Jolanta Kupryjanczyk; Linda S Cook; Nhu D Le; Angela Brooks-Wilson Journal: Hum Genet Date: 2013-11-05 Impact factor: 4.132
Authors: Zeliha Firat Cuylan; Emine Karabuk; Murat Oz; Ahmet Taner Turan; Mehmet M Meydanli; Salih Taskin; Mustafa Erkan Sari; Hanifi Sahin; Suat C Ulukent; Ozgur Akbayir; Kemal Gungorduk; Tayfun Gungor; Mehmet F Kose; Ali Ayhan Journal: J Ovarian Res Date: 2018-10-30 Impact factor: 4.234